Recalls & Warnings
ConsumerLab.com is keeping you informed with current product recalls and warnings.
Latest Posted October 2, 2023
On September 29, 2023, the FDA warned consumers that the following arthritis and pain management products contain undeclared drugs such as diclofenac, methocarbamol (a muscle relaxant), and dexamethasone (a corticosteroid), and/or other potentially harmful ingredients. Use the links below for more information about each product.
- Kuka Flex Forte
- Reumo Flex
- Tapee Tea (see previous warning)
- Fast-Act Rheuma Capsule
- New Fast-Act Rheumatism Capsule
- AK Forte
- Artri King (see previous warning)
- Ortiga Mas Ajo Rey (see previous warning)
- Ortiga Mas Ajo Rey Extra Forte (see previous warning)
Undeclared drugs and other ingredients in these products can cause adverse effects such as low blood pressure, sedation and dizziness, infections, increased blood sugar, bone damage, and psychiatric problems. Consumers who have been taking these products should consult with their healthcare provider before discontinuing, as suddenly stopping corticosteroids after long-term use can result in withdrawal syndrome.
Consumers and healthcare providers can report any adverse reactions to the FDA’s MedWatch Voluntary Reporting Program.
See ConsumerLab’s Review of Joint Health Supplements for more information about related products.
Also see ConsumerLab’s article about supplements promoted to help with arthritis.
For more information, use the link below.
Tainted Arthritis | Pain Products
See related recalls and warnings:
Walmart Inc. Recalls Joint Supplements With Omega-3, Glucosamine & CurcuminWalmart Inc. Recalls Joint Supplements With Omega-3, Glucosamine & Curcumin
Prescription Drugs Found in Arthritis, Muscle Pain, and Osteoporosis Supplements
Pharmaceutical Drugs Found In Dietary Supplements Pose Danger to Consumers
Recall: Arthritis and Muscle Pain Supplement Contains Prescription Drugs
Arthritis Supplement Containing Multiple Drugs Recalled
For information about reporting serious reactions and problems with medical products to the U.S. Food and Drug Administration through its MedWatch reporting program, please visit the FDA MedWatch website.